Document is current
Any future updates will be listed below
-
Authors
Khalid, Sara
Alhambra, Daniel Prieto
Hasheminasab, Seyed Alireza
Vinogradova, Yana
Qureshi, Nadeem
Ratzinger, Michaela
Brunetti, Vanessa
Salas, Adrian
Canals, Laura
-
Funding
Funding for this research was provided by:
Amgen
- License Information
-
More Information
Article History
Received: 24 June 2024
Accepted: 7 December 2024
First Online: 28 January 2025
Declarations
:
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Patients had already provided informed consent for their data to be collected in UK CPRD; therefore, no informed consent was required this study.
: Sara Khalid has received funding for Amgen related to this work, and from UCB Biopharma, URKI, HDRUK, NIHR, Alan Turing Institute and the Bill & Melinda Gates Foundation outside of this work. Daniel Prieto Alhambra’s department has received grant/s from Amgen, Chiesi-Taylor, Lilly, Janssen, Novartis and UCB Biopharma. His research group has received consultancy fees from Astra Zeneca and UCB Biopharma. Amgen, Astellas, Janssen, Synapse Management Partners and UCB Biopharma have funded or supported training programmes organized by DPA's department. Michaela Ratzinger, Vanessa Brunetti, Adrian Salas and Laura Canals are Amgen employees and stakeholders. Seyed Alireza Hasheminasab, Yana Vinogradova and Nadeem Qureshi have nothing to declare.
